HK1199838A1 - 大環 激酶抑制劑 - Google Patents

大環 激酶抑制劑

Info

Publication number
HK1199838A1
HK1199838A1 HK15100389.2A HK15100389A HK1199838A1 HK 1199838 A1 HK1199838 A1 HK 1199838A1 HK 15100389 A HK15100389 A HK 15100389A HK 1199838 A1 HK1199838 A1 HK 1199838A1
Authority
HK
Hong Kong
Prior art keywords
lrrk2
macrocyclic
kinase inhibitors
lrrk2 kinase
inhibitors
Prior art date
Application number
HK15100389.2A
Other languages
English (en)
Inventor
Jan Hoflack
Petra Blom
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of HK1199838A1 publication Critical patent/HK1199838A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
HK15100389.2A 2011-09-30 2015-01-14 大環 激酶抑制劑 HK1199838A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2011067086 2011-09-30
PCT/IB2012/002318 WO2013046029A1 (en) 2011-09-30 2012-09-28 Macrocyclic lrrk2 kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1199838A1 true HK1199838A1 (zh) 2015-07-24

Family

ID=47326223

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100389.2A HK1199838A1 (zh) 2011-09-30 2015-01-14 大環 激酶抑制劑

Country Status (18)

Country Link
US (2) US9096609B2 (zh)
EP (1) EP2760453B1 (zh)
JP (1) JP6082397B2 (zh)
KR (1) KR20140095477A (zh)
CN (1) CN104023728B (zh)
AU (1) AU2012314035B2 (zh)
BR (1) BR112014007654A8 (zh)
CA (1) CA2850350A1 (zh)
DK (1) DK2760453T3 (zh)
ES (1) ES2583477T3 (zh)
HK (1) HK1199838A1 (zh)
HU (1) HUE029728T2 (zh)
MX (1) MX342177B (zh)
PL (1) PL2760453T3 (zh)
PT (1) PT2760453T (zh)
RU (1) RU2622104C2 (zh)
UA (1) UA113186C2 (zh)
WO (1) WO2013046029A1 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6046728B2 (ja) * 2011-09-30 2016-12-21 オンコデザイン エス．ア． 大環状ｆｌｔ３キナーゼ阻害剤
MD20140130A2 (ro) 2012-06-29 2015-04-30 Pfizer Inc. 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
AU2014230111A1 (en) * 2013-03-15 2015-10-29 Oncodesign S.A Macrocyclic RIP2 kinase inhibitors
AU2014230485A1 (en) * 2013-03-15 2015-09-24 Oncodesign S.A. Macrocyclic LRRK2 kinase inhibitors
SG11201507493SA (en) * 2013-03-15 2015-10-29 Oncodesign Sa Macrocyclic salt-inducible kinase inhibitors
AU2014264973B2 (en) * 2013-05-06 2018-01-18 Merck Patent Gmbh Macrocycles as kinase inhibitors
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
WO2015136073A1 (en) * 2014-03-14 2015-09-17 Oncodesign Sa Macrocyclic tgf-br2 kinase inhibitors
EP3166637B1 (en) 2014-07-10 2020-01-29 The J. David Gladstone Institutes Compositions and methods for treating dengue virus infection
CA2958782C (en) 2014-09-17 2024-01-09 Oncodesign S.A. Macrocyclic rip2 kinase inhibitors
CA2960777A1 (en) * 2014-09-17 2016-03-24 Oncodesign S.A. Macrocyclic lrrk2 kinase inhibitors
WO2016146651A1 (en) 2015-03-16 2016-09-22 Oncodesign Sa Macrocyclic activin-like receptor kinase inhibitors
WO2017046675A1 (en) 2015-09-14 2017-03-23 Pfizer Inc. Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
CA3031100A1 (en) * 2016-07-28 2018-02-01 Tp Therapeutics, Inc. Macrocycle kinase inhibitors
CN110678182B (zh) * 2017-02-24 2022-08-23 大邱庆北尖端医疗产业振兴财团 含有能够穿透血脑屏障的化合物作为预防或治疗脑癌的有效成分的药物组合物
BR112020000772A2 (pt) * 2017-07-14 2020-07-21 Glaxosmithkline Intellectual Property Development Limited inibidores de cinase 2 de repetição rica em leucina
CN110627812B (zh) 2018-06-25 2022-10-11 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
BR112021007679A2 (pt) 2018-10-22 2021-07-27 Esker Therapeutics, Inc inibidores de tyk2 e seus usos
BR112022022511A2 (pt) * 2020-05-06 2022-12-13 Servier Lab Inibidores macrocíclicos de lrrk2 quinase
IL305877A (en) * 2021-03-18 2023-11-01 Servier Lab Macrocyclic LRRK2 kinase inhibitors
WO2023073013A1 (en) * 2021-10-27 2023-05-04 H. Lundbeck A/S Lrrk2 inhibitors
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
CN117425660A (zh) * 2022-05-18 2024-01-19 上海翊石医药科技有限公司 一种芳杂环类化合物及其中间体、药物组合物和用途
WO2023224894A1 (en) * 2022-05-20 2023-11-23 Merck Sharp & Dohme Llc Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
CZ289214B6 (cs) 1993-10-01 2001-12-12 Astra Aktiebolag Způsob zpracování jemně děleného práąkového léčiva, zařízení k provádění tohoto způsobu a aglomeráty vyrobené tímto způsobem
EP0729758A3 (en) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
ATE375344T1 (de) 1996-07-24 2007-10-15 Bristol Myers Squibb Pharma Co Azolotriazine und pyrimidine
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
KR100843281B1 (ko) 2000-12-28 2008-07-09 오노 야꾸힝 고교 가부시키가이샤 삼환식 복소환 유도체 화합물 및 그 화합물을 유효성분으로 하는 의약
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE602004012891T2 (de) * 2003-12-18 2009-04-09 Janssen Pharmaceutica N.V. Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel
US8029986B2 (en) 2004-10-21 2011-10-04 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt(GmbH) KASPP (LRRK2) gene, its production and use for the detection and treatment of neurodegenerative disorders
NO323175B1 (no) 2004-12-23 2007-01-15 Jan O Aasly Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme
FI123725B (fi) 2005-08-01 2013-10-15 Reijo Viljanen Menetelmä sahalaitteen terän jännittämiseksi ja ohjaamiseksi sekä ohjaus- ja jännityslaitteet
US7750000B2 (en) * 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
TWI525096B (zh) * 2005-11-16 2016-03-11 Ｃｔｉ生技製藥有限公司 氧連接之嘧啶衍生物
KR101546493B1 (ko) * 2006-11-06 2015-08-21 톨레로 파마수티컬스, 인크. 이미다조[1,2-ｂ]피리다진 및 피라졸로[1,5-ａ]피리미딘 유도체 및 단백질 키나제 억제제로서의 이의 용도
WO2008060248A1 (en) * 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
JP2010513450A (ja) * 2006-12-20 2010-04-30 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 抗ウイルス性インドール
US7732434B2 (en) * 2007-04-20 2010-06-08 Bristol-Myers Squibb Company Macrocyclic acyl guanidines as beta-secretase inhibitors
AU2008281849B2 (en) * 2007-07-27 2013-11-28 Janssen Pharmaceutica Nv Pyrrolopyrimidines
DK2283024T3 (da) * 2008-03-10 2013-08-05 Janssen Pharmaceutica Nv 4-aryl-2-anilinpyrimidiner som PLK-kinaseinhibitorer
DE102008019146A1 (de) 2008-04-16 2009-11-05 Airbus Deutschland Gmbh Enteisungssystem für ein Flugzeug
KR101700229B1 (ko) * 2009-03-19 2017-01-26 메디칼 리서치 카운실 테크놀로지 화합물들
KR101438293B1 (ko) * 2009-09-21 2014-09-05 에프. 호프만-라 로슈 아게 Ｊａｋ의 매크로사이클릭 억제자
ES2512727T3 (es) 2009-09-29 2014-10-24 Glaxo Group Limited Nuevos compuestos
MX349366B (es) * 2011-05-19 2017-07-26 Centro Nac De Investigaciones Oncologicas (Cnio) Compuestos novedosos.
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
JP6046728B2 (ja) * 2011-09-30 2016-12-21 オンコデザイン エス．ア． 大環状ｆｌｔ３キナーゼ阻害剤

Also Published As

Publication number Publication date
EP2760453B1 (en) 2016-05-25
ES2583477T3 (es) 2016-09-21
AU2012314035A1 (en) 2014-05-15
DK2760453T3 (en) 2016-08-15
HUE029728T2 (en) 2017-03-28
MX342177B (es) 2016-09-20
PT2760453T (pt) 2016-08-02
RU2014117515A (ru) 2015-11-10
CA2850350A1 (en) 2013-04-04
JP6082397B2 (ja) 2017-02-15
US20140206683A1 (en) 2014-07-24
MX2014003557A (es) 2014-11-26
JP2014528405A (ja) 2014-10-27
WO2013046029A1 (en) 2013-04-04
BR112014007654A2 (pt) 2018-04-17
PL2760453T3 (pl) 2016-11-30
KR20140095477A (ko) 2014-08-01
US20150290198A1 (en) 2015-10-15
AU2012314035B2 (en) 2016-12-15
CN104023728B (zh) 2016-11-02
UA113186C2 (xx) 2016-12-26
US9096609B2 (en) 2015-08-04
CN104023728A (zh) 2014-09-03
EP2760453A1 (en) 2014-08-06
US9370520B2 (en) 2016-06-21
BR112014007654A8 (pt) 2018-06-12
RU2622104C2 (ru) 2017-06-13

Similar Documents

Publication Publication Date Title
HK1199838A1 (zh) 大環 激酶抑制劑
HK1200828A1 (zh) 激酶抑制劑
HK1198764A1 (zh) 大環 激酶抑制劑
PL2710007T3 (pl) Inhibitory kinazy
IL228103A0 (en) Amino-quinolines as kinase inhibitors
EP2782580A4 (en) SELECTIVE INHIBITORS OF KINASES
IL229028A0 (en) Kinase inhibitors
GB201009731D0 (en) Kinase inhibitors
HK1199873A1 (zh) 激酶抑制劑
IL232234A0 (en) Inhibitors of aminopyrimidine kinase
IL228928A0 (en) Aminopyrimidine kinase inhibitors
EP2685992A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
AP2013007215A0 (en) Imidazopyridazines as AKT kinase inhibitors
HK1201460A1 (zh) 吡嗪激酶抑制劑
HK1219481A1 (zh) 大環的 激酶抑制劑
PL2646448T3 (pl) Makrocykliczne inhibitory kinazy
PL2760867T3 (pl) Makrocykliczne inhibitory kinaz FLT3

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200930